Abstract
There is a wide variation in cancer incidence in humans, which, in part, has been attributed to metabolic factors of carcinogens and genetic polymorphisms in drug metabolising enzymes and drug transporters. Drug metabolising enzymes are responsible for the initial activation of many (pro)carcinogens, such as polycyclic aromatic hydrocarbons (PAH), to biologically reactive metabolites. Besides, detoxifying enzymes are responsible for the inactivation of these active carcinogens and deficiency of these enzymes may result in an increase of cancer risk in exposed individuals. Another factor influencing interindividual variability in cancer incidence is the transporters, which are responsible for the excretion of carcinogens. A high number of polymorphisms have been described in drug metabolising enzymes and drug transporter genes. These polymorphisms might influence the activity of metabolising enzymes and drug transporters and thereby affect cancer risk. This review will focus on the role of genetic polymorphisms of selected drug metabolising enzymes (CYP1A1, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, GSTP1, GSTT1, SULT1A1, NAT1 and NAT2) and ABCtransporters (P-gp and BRCP) in relation to cancer risk.
Keywords: Polymorphisms, drug-metabolising enzymes, drug transporters, cancer risk
Current Cancer Therapy Reviews
Title: Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Volume: 2 Issue: 2
Author(s): Tessa M. Bosch, Irma Meijerman, Jos H. Beijnen and Jan H.M. Schellens
Affiliation:
Keywords: Polymorphisms, drug-metabolising enzymes, drug transporters, cancer risk
Abstract: There is a wide variation in cancer incidence in humans, which, in part, has been attributed to metabolic factors of carcinogens and genetic polymorphisms in drug metabolising enzymes and drug transporters. Drug metabolising enzymes are responsible for the initial activation of many (pro)carcinogens, such as polycyclic aromatic hydrocarbons (PAH), to biologically reactive metabolites. Besides, detoxifying enzymes are responsible for the inactivation of these active carcinogens and deficiency of these enzymes may result in an increase of cancer risk in exposed individuals. Another factor influencing interindividual variability in cancer incidence is the transporters, which are responsible for the excretion of carcinogens. A high number of polymorphisms have been described in drug metabolising enzymes and drug transporter genes. These polymorphisms might influence the activity of metabolising enzymes and drug transporters and thereby affect cancer risk. This review will focus on the role of genetic polymorphisms of selected drug metabolising enzymes (CYP1A1, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, GSTP1, GSTT1, SULT1A1, NAT1 and NAT2) and ABCtransporters (P-gp and BRCP) in relation to cancer risk.
Export Options
About this article
Cite this article as:
Bosch M. Tessa, Meijerman Irma, Beijnen H. Jos and Schellens H.M. Jan, Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872825
DOI https://dx.doi.org/10.2174/157339406776872825 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Generation of Redox Imbalance Mediates the Cytotoxic Effect of Malabaricone-A in a Multidrug Resistant Cell Line
Anti-Cancer Agents in Medicinal Chemistry α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients
Recent Patents on Cardiovascular Drug Discovery Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma
Current Cancer Drug Targets Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design